Abstracts tagged "Vasculitis"

Abstract Number: 1626 • ACR Convergence 2024
Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review
Sagar Patel¹, Iva Okaj², Jessica Scott³, Sukhreet Atwal³, Colin Stark³, Rabia Tahir³, Nader Khalidi² and Mats Junek², ¹McMaster University, Brampton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³McMaster University, Hamilton, Canada
Background/Purpose: Giant cell arteritis is being increasingly recognized to occur in intracranial vessels. The clinical significance of intracranial GCA (ICGCA) is unknown; previous cases have…
Abstract Number: 2161 • ACR Convergence 2024
Parent and Youth Report of Psychosocial Functioning in Chronic Childhood Vasculitis
Camille Wilson¹, Kimberly Morishita², Else Bosman³, Alana Leever⁴, Mahmoud Kallash⁵, Anne Dawson¹, David Cabral⁶ and Vidya Sivaraman⁷, and the PedVas investigator network, ¹Nationwide Children's Hospital, Columbus, OH, ²University of British Columbia - Vancouver, Vancouver, BC, Canada, ³UBC, Vancouver, BC, Canada, ⁴Nationwide Children's Hospital, Ohio State University, Columbus, OH, ⁵Nationwide Children's Hosptial, Columbus, OH, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Nationwide Children's Hospital/ The Ohio State University, Columbus, OH
Background/Purpose: Collaborative research efforts have allowed great strides to advance treatment and care for pediatric patients living with chronic vasculitis. However, little research has been…
Abstract Number: 2504 • ACR Convergence 2024
Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study
Paul Cioni¹, Yann Nguyen², Julien ROHMER³, Henry Dupuy⁴, Xavier Puéchal⁵, Estibaliz Lazaro⁶, Grégory Pugnet⁷, Cécile-Audrey Durel⁸, Edoardo Conticini⁹, François Lifermann¹⁰, Philip Bielefeld¹¹, pierre duffau⁴, Hartmut Mahrhofer¹², Alexis Régent⁵, Loïc Guillevin¹³, ludovic trefond¹⁴, Christian AGARD¹⁵, Alice Bérezné¹⁶, Valentin Lacombe¹⁷, Perrine SMETS¹⁸, Sophie Georgin-lavialle¹⁹, Arsene Mekinian²⁰ and Benjamin Terrier²¹, and the French Vasculitis Study Group and the French Vexas Group, ¹Cochin University Hospital, Paris, France, ²Université Paris Saclay, Clichy, Ile-de-France, France, ³APHP, Suresnes, France, ⁴Bordeaux University Hospital, Bordeaux, France, ⁵National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁶Bordeaux University Hospital, Pessac, France, ⁷Toulouse Rangueil University Hospital, Toulouse, France, ⁸Edouard Herriot University Hospital, Lyon, France, ⁹University of Siena, Siena, Siena, Italy, ¹⁰Dax Hospital, Dax, France, Dax, France, ¹¹Dijon University Hospital, Dijon, France, ¹²Kirchheim Clinic, Kirchheim unter Teck, Germany, ¹³National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ¹⁴Clermont Ferrand University Hospital, Clermont Ferrand, France, ¹⁵Nantes University Hospital, Nantes, France, ¹⁶Annecy Genevois Hospital, Annecy, France, ¹⁷Angers University Hospital, Angers, France, ¹⁸Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ¹⁹Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²⁰Saint Antoine University Hospital, Paris, France, ²¹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis affecting medium-sized vessels. It is a life-threatening disease without appropriate treatment. In 2024, approximately one quarter…
Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
James Bistolarides¹, Vidya Sivaraman², Else Bosman³, Linda Wagner-Weiner⁴, Kimberly Morishita⁵, James Nocton¹, Melodee Liegl¹, Amy Pan¹ and David Cabral⁶, and PedVas Investigators Network, ¹Medical College of Wisconsin, Milwaukee, WI, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³UBC, Vancouver, BC, Canada, ⁴University of Chicago, Chicago, IL, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
Abstract Number: 0737 • ACR Convergence 2024
Rurality and Delayed Diagnosis of Giant Cell Arteritis – a Single Center Experience
Ruoning (Lemon) Ni¹, Bharat Kumar² and Aleksander Lenert³, ¹Cleveland Clinic, Cleveland, OH, ²University of Iowa Hospitals and Clinics, Iowa City, IA, ³University of Iowa, Iowa City, IA
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges, especially in rural areas, where limited access to healthcare can delay diagnosis and worsen outcomes, a concern…
Abstract Number: 0766 • ACR Convergence 2024
Neutrophil Transcriptomics in VEXAS Syndrome
Chloe Palmer¹, Gustaf Wigerblad¹, Tom Hill², Bhavisha Patel³, Emma Groarke⁴, Neal Young⁴, Stefania Dell'Orso⁵ and Peter Grayson⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ³National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations of the ubiquitin-like modifier activating enzyme 1 (UBA1) gene and…
Abstract Number: 1597 • ACR Convergence 2024
Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis
Naomi Patel¹, Sarah Bray², Darcy Trimpe³, David Jayne⁴, Peter Merkel⁵ and John Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Amgen Ltd, Cambridge, United Kingdom, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: The ADVOCATE trial evaluated avacopan (a C5a receptor antagonist) as a replacement for a standard prednisone taper in the treatment of granulomatosis with polyangiitis…
Abstract Number: 1630 • ACR Convergence 2024
Disease Manifestations, Diagnostic Findings, and Mortality of 120 Consecutive Patients Suspected of Giant Cell Arteritis – Results from a Hospital GCA Fast-Track Clinic
Uffe Moller Dohn¹, Tanja Fromberg Gorlen², Rikke Westergaard¹, Viktoria Fana¹, Torsten Møller¹ and Lene Terslev³, ¹Rigshospitalet-Glostrup, Glostrup, Denmark, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Hovedstaden, Denmark, ³Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis affecting the large vessels from aorta, its proximal branches, and the extra-cranial arteries. To avoid ischemic…
Abstract Number: 2180 • ACR Convergence 2024
The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis
Jessica Bloom¹, Kaci Pickett-Nairne², Lori Silveira², David Cuthbertson³, Carol McAlear⁴, Peter Merkel⁴ and Karen James⁵, and the Vasculitis Clinical Research Consortium, ¹University of Colorado, Denver, CO, ²University of Colorado, Aurora, CO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Utah, Salt Lake City, UT
Background/Purpose: Vasculitis is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether the degree of this impact varies based…
Abstract Number: 2505 • ACR Convergence 2024
C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?
Joao Carlos Batista-Liz¹, Vanesa Calvo-Rio², María Sebastián Mora-Gil³, Ligia Gabrie-Rodriguez⁴, Rafael Gálvez Sánchez⁴, Belén Sevilla-Pérez⁵, José Luis Callejas⁶, María Teresa Leonardo⁷, Ana Peñalba⁷, Javier Narvaez-García⁸, Luis Martín-Penagos⁹, Luis Caminal-Montero¹⁰, PAZ COLLADO¹¹, Patricia Quiroga Colina¹², Esther Vicente-rabaneda¹³, Esteban Rubio¹⁴, Manuel León Luque¹⁵, Juan María Blanco-Madrigal¹⁶, Eva Galindez-Agirregoikoa¹⁷, Santos Castañeda¹³, Ricardo Blanco-Alonso¹⁸, Veronica Pulito-Cueto¹ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Valdecilla Hospital, Santander, Cantabria, Spain, ³Immunopathology Group, IDIVAL, Santander, Spain, ⁴Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁶Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ⁷Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ¹¹Hospital Universitario Severo Ochoa, MADRID, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, Sevilla, Spain, ¹⁵Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Sevilla, Spain, ¹⁶Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain., Bilbao, Spain, ¹⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…
Abstract Number: 2647 • ACR Convergence 2024
Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a DADA2 Cohort of 101 Patients
Aman Sharma¹, Niladri Bhowmick², shankar naidu³, Varun Dhir⁴, Prateek Bhatia³, Vishal Sharma³, sagar Bhattad⁵, Chengappa Kavadichanda⁶, Vikas Gupta⁷, Durga P Misra⁸, Sourabh Malviya⁹, DUDAM RAJKIRAN¹⁰, Banwari Sharma¹¹, John Mathew¹², Sathish Kumar¹³, Rajesh Bhojwani¹⁴, Aadhaar Dhooria¹⁵, Avinash Jain¹⁶, Pankaj Gupta¹⁷, Vikas Agarwal⁸, Rudrarpan Chatterjee¹⁸, Kusum Sharma¹⁹, Manphool Singhal¹⁹, Harjeet Singh¹⁹, Alpana Parmar²⁰, Padmanbha Shenoy²¹, Ritambhra Nada¹⁹, Ranjana Minz¹⁹, Archana Khan²², Sodality Sutnga²², Minu Singh¹⁹, Kaushik Bhojani²³, MAHABALESHWAR MAMADAPUR²⁴, Manesh Manoj²⁵, Puja Srivastava²⁶, Adarsh MB²⁷, Kavita Krishna²⁸, Ramesh Jois²⁹, Vir Singh Negi³⁰, Amita Aggarwal³¹, sanjay jain¹⁹, Raju Khubchandani³², Chip Chambers³³ and Pui Lee³⁴, ¹PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ²Post Graduate Institute of Medical Education and Research , Chandigarh, Chandigarh, Chandigarh, India, ³PGIMER, Chandigarh, India, Chandigarh, India, ⁴PGIMER, CHD, INDIA, CHANDIGARH, India, ⁵2Aster CMI Hospital, Bengaluru, India, Bengaluru, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Fortis Hospital, Ludhiana, India, Ludhiana, ⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁹Medanta superspeciality hospital, Indore, India, ¹⁰Hyderabad Rheumatology Centre, Hyderabad, India, HYDERABAD, Andhra Pradesh, India, ¹¹Niramaya Healthcare, Jaipur, India, Jaipur, India, ¹²Christian Medical college , Vellore , India, Vellore, India, ¹³CMC, Vellore, Vellore, India, ¹⁴Santokba Durlabhji Memorial Hospital, Jaipur, India, Jaipur, India, ¹⁵Mahatma Gandhi Medical College and Hospital Jaipur, Jaipur, Rajasthan, India, ¹⁶Sawai Man Singh Hospital, Lucknow, Rajasthan, India, ¹⁷PGIMER, Chandigarh, India, Chandigarh, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ¹⁹PGIMER, Chandigarh, Chandigarh, India, ²⁰Rheumatology Clinic, Surat, India, Surat, India, ²¹Center for arthritis and rheumatims excellence ( CARE, Cochin, Kerala, India, ²²SRCC Children’s Hospital, Mumbai, India, Mumbai, India, ²³Fortis Hospital, Mumbai, Mumbai, India, ²⁴JSS MEDICAL COLLEGE AND HOSPITAL,JSSAHER, Mysore, Karnataka, India, ²⁵AKG Memorial Cooperative Hospital Kannur, Nileshwar, Kerala, India, ²⁶STAR Rheumatology Clinics, Ahmedabad, India, Ahmedabad, India, ²⁷Government Medical College, Kozhikode, India, Kozhikode, India, ²⁸Bharati Vidyapeeth Medical College, Pune, Pune, India, ²⁹Manipal Hospital ,Rheumatology, Millers Road, Bengaluru, India, Bengaluru, India, ³⁰AIIMS, Bilaspur, Puducherry, Puducherry, India, ³¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ³²SRCC Childrens Hospital, Mumbai, India, ³³Vanderbilt University Medical Center & DADA2 Foundation, Franklin, TN, ³⁴Boston Children's Hospital, Newton, MA
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is a rare and potentially life threatening monogenic disorder characterized by systemic vasculitis, bone marrow failure, and immunodeficiency.…
Abstract Number: 0742 • ACR Convergence 2024
Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab
Kaitlin Quinn¹, mark ahlman² and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Radiology and Imaging, Medical College of Georgia, augusta, GA, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: The optimal way to monitor disease activity in patients with GCA on tocilizumab remains uncertain. Acute phase reactants are not a reliable indicator of…
Abstract Number: 0767 • ACR Convergence 2024
Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis
Alison Clifford¹, Jonathan Abele¹, Ryan Hung¹, Paolo Raggi¹, Frank Wuest¹, Jan Andersson¹, Elaine Yacyshyn², Eric Lenza¹, Glen Jickling¹ and Jan Willem Cohen Tervaert¹, ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: 18F-fluoro-deoxyglucose (FDG) is the current standard among radiotracers for PET/CT imaging of large vessel vasculitis (LVV) in giant cell arteritis (GCA), but its performance…
Abstract Number: 1598 • ACR Convergence 2024
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Naomi Patel¹, Aaron Wu¹, Shruthi Srivatsan¹, Eli Miloslavsky², Peter Merkel³, John Stone⁴, Hyon K. Choi⁵, Emily Hyle¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…
Abstract Number: 1632 • ACR Convergence 2024
Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?
Augustine Jose¹, Molly Thabah², Chengappa Kavadichanda³, Jagan K L², Christina Mariaselvam⁴ and Vir Singh Negi⁵, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁴JIPMER, Puducherry, Puducherry, India, ⁵AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Ultrasonography can measure vascular intimal-medial thickness (IMT) and delineate the degrees of stenosis in Takayasu arteritis (TAK). Further, higher IMT has been reported in…

« Previous Page
1
…
3
4
5
6
7
…
35
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].